IL17A and myeloid sarcoma: Both cytokines IL-17a and TNFα were significantly under-expressed in MS patients that showed a significant down-regulation of miR-155 and miR-26a after drug treatment (Fig 4B and 4C), whereas IFN γ and IL-6 mRNA levels were not significantly decreased in the same MS group (Fig 4D and 4E)].